BACKGROUND: The manifestations of atherothrombosis such as myocardial infarction,
ischemic stroke, limb ischemia, or cardiovascular death pose a global health care burden …

Large randomized clinical trials have made a major contribution to advances in the
management of cardiovascular disease, and provide the most reliable evidence for clinical …

The recent CAPRIE trial (clopidogrel versus aspirin in patients at risk of ischaemic events)
compared clopidogrel with aspirin in reducing the risk of vascular events in 19 185 patients …

BACKGROUND: Late discontinuation of clopidogrel after an acute coronary syndrome or
stent placement may be associated with a clinical rebound effect. AIMS: To describe the …

[From multicenter trial to national registries: the truth about the management of myocardial
infarction]. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu …

Background In an active-control trial with a new treatment and a comparator that has
placebo-controlled trials, how might the effect of the new therapy versus placebo be …

Because of the central role of platelets in mediating ischemic events, antiplatelet agents are
critical components of atherothrombosis prevention. Given their robust safety and efficacy …

Given all the technology that we have access to today, we should be drastically reducing
coronary disease, but obviously we're not. In the year 2020, we are projected to see a …

PURPOSE: Clopidogrel is more effective than aspirin in preventing recurrent vascular
events, but concerns about its cost-effectiveness have limited its use. We evaluated the cost …

This paper describes some important controversies regarding the current state of clinical
trials research in cardiology. Topics covered include the inadequacy of trial research on …